Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL3 | Q96JM7 | 11/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 9/20 | 0.51 |
| ▸ | ACHE | P22303 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
| ▸ | MBTD1 | Q05BQ5 | 4/20 | 0.41 |
| ▸ | TP53BP1 | Q12888 | 1/20 | 0.41 |
| ▸ | L3MBTL4 | Q8NA19 | 1/20 | 0.41 |
| ▸ | TGM2 | P21980 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | USP5 | P45974 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4461999 | 0.93 | L3MBTL3 (0.54) | L3MBTL3L3MBTL1ACHEALDH1A1MBTD1 | |
| SCHEMBL1464487 | 0.92 | L3MBTL3 (0.55) | L3MBTL3L3MBTL1ACHEALDH1A1TDP1 | |
| SCHEMBL2550326 | 0.87 | L3MBTL3 (0.46) | L3MBTL3L3MBTL1ALDH1A1TDP1TP53 | |
| SCHEMBL12881316 | 0.86 | L3MBTL3 (0.50) | L3MBTL3L3MBTL1ACHEALDH1A1TDP1 | |
| SCHEMBL27932674 | 0.86 | L3MBTL3 (0.53) | L3MBTL3L3MBTL1ACHEALDH1A1TDP1 | |
| SCHEMBL4471423 | 0.85 | L3MBTL3 (0.57) | L3MBTL3L3MBTL1ALDH1A1HRH3MBTD1 | |
| SCHEMBL8136294 | 0.84 | CYP1A2 (0.61) | L3MBTL3L3MBTL1ACHEALDH1A1TDP1 | |
| SCHEMBL14899995 | 0.82 | L3MBTL3 (0.50) | L3MBTL3L3MBTL1ACHEALDH1A1TDP1 | |
| SCHEMBL4706209 | 0.82 | ACACB (0.44) | L3MBTL3L3MBTL1TDP1TP53MBTD1 | |
| SCHEMBL2862492 | 0.81 | L3MBTL3 (0.58) | L3MBTL3L3MBTL1MBTD1TP53BP1L3MBTL4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101952276-B | 5-halo substituted oxindole derivatives and their use for the treatment of vasopressin dependent diseases | ABBOTT GMBH & CO.KG (DE) | 2014-10-22 | — | — | CN | claimed |
| CN-109970743-B | 5-chloro-2-difluoromethoxyphenyl pyrazolopyrimidine compounds as JAK inhibitors | 豪夫迈·罗氏有限公司 | 2022-03-04 | — | — | CN | disclosed |
| EP-2952510-B1 | SUBSTITUTED 2-AMINOPYRIDINE PROTEIN KINASE INHIBITOR | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO LTD (CN) | 2018-12-26 | — | — | EP | disclosed |
| US-20150158845-A1 | 5-HALOGEN-SUBSTITUTED OXINDOLE DERIVATIVES AND USE THEREOF FOR TREATING VASOPRESSIN-DEPENDENT DISEASES | ABBVIE DEUTSCHLAND (DE) | 2015-06-11 | — | — | US | disclosed |
| US-9023854-B2 | 5-halogen-substituted oxindole derivatives and use thereof for treating vasopressin-dependent diseases | AbbVie Deutschland GmbH & Co. KG (DE) | 2015-05-05 | — | — | US | disclosed |
| CN-101952276-B | 5-halo substituted oxindole derivatives and their use for the treatment of vasopressin dependent diseases | ABBOTT GMBH & CO.KG (DE) | 2014-10-22 | — | — | CN | disclosed |
| EP-2546250-A1 | Heteroaryl-substituted 1,3 dihydroindol-2-one derivatives and medicaments containing them | Abbott GmbH & Co. KG (DE) | 2013-01-16 | — | — | EP | disclosed |
| EP-2546252-A1 | Heteroaryl-substituted 1,3 dihydroindol-2-one derivatives and medicaments containing them | Abbott GmbH & Co. KG (DE) | 2013-01-16 | — | — | EP | disclosed |
| EP-1719762-B1 | NOVEL PYRIDINE DERIVATIVE AND PYRIMIDINE DERIVATIVE (1) | EISAI R&D MAN CO LTD (JP) | 2012-06-27 | — | — | EP | disclosed |
| CN-101952276-A | 5-halo substituted oxindole derivatives and their use for the treatment of vasopressin dependent diseases | ABBOTT GMBH & CO KG | 2011-01-19 | — | — | CN | disclosed |
| US-20100311972-A1 | METHOD FOR PRODUCING PHENOXYPYRIDINE DERIVATIVE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-12-09 | — | — | US | disclosed |
| EP-2248810-A1 | METHOD FOR PRODUCING PHENOXYPYRIDINE DERIVATIVE | Eisai R&D Management Co., Ltd. (JP) | 2010-11-10 | — | — | EP | disclosed |
| US-7531532-B2 | Hepatocyte growth factor receptor inhibitors; Antitumor agents, anticarcinogenic agents, angiogenesis inhibitors; pyrimidine derivatives like Pyrrolidine-1-carboxylic acid [6-(2-fluoro-4-{3-[2-(4-fluorophenyl)acetyl]thioureido}phenoxy)pyrimidin-4-yl]amide | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-05-12 | — | — | US | disclosed |
| EP-1950199-A1 | Proline derivatives and use thereof as drugs | Mitsubishi Tanabe Pharma Corporation (JP) | 2008-07-30 | — | — | EP | disclosed |
| EP-1930319-A1 | Proline derivatives and use thereof as drugs | Mitsubishi Tanabe Pharma Corporation (JP) | 2008-06-11 | — | — | EP | disclosed |
| US-20070270421-A1 | Novel pyridine Derivative and Pyrimidine Derivative (1) | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2007-11-22 | — | — | US | disclosed |
| CN-1906166-A | Novel pyridine derivative and pyrimidine derivative (1) | EISAI CO LTD (JP) | 2007-01-31 | — | — | CN | disclosed |
| EP-1719762-A1 | NOVEL PYRIDINE DERIVATIVE AND PYRIMIDINE DERIVATIVE (1) | Eisai Co., Ltd. (JP) | 2006-11-08 | — | — | EP | disclosed |
| US-20050277652-A1 | Novel pyridine derivative and pyrimidine derivative | EISAI CO., LTD. (JP) | 2005-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070270421-A1 | Novel pyridine Derivative and Pyrimidine Derivative (1) | HGF, MET, FLT1 | L3MBTL3 1125/4885L3MBTL1 1054/4885ACHE 4805/4885 |
| US-20100311972-A1 | METHOD FOR PRODUCING PHENOXYPYRIDINE DERIVATIVE | TET2, QDPR, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | L3MBTL3 4422/4885L3MBTL1 4586/4885ACHE 2353/4885 |
| US-20050277652-A1 | Novel pyridine derivative and pyrimidine derivative | HGF, MET, HDGF | L3MBTL3 1402/4885L3MBTL1 1338/4885ACHE 4843/4885 |
| US-20150158845-A1 | 5-HALOGEN-SUBSTITUTED OXINDOLE DERIVATIVES AND USE THEREOF FOR TREATING VASOPRESSIN-DEPENDENT DISEASES | AVPR2, AVPR1B, AVPR1A | L3MBTL3 1922/4885L3MBTL1 2942/4885ACHE 3442/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.